Attenuation of LPS-induced lung inflammation by Glucosamine in rats

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 6, 2013, Pages 1110-1119

  Chuang, Kun Han ^a   Peng, Yen Chun ^b   Chien, Han Yun ^a   Lu, Meng Lun ^a   Du, Hsin I ^a   Wu, Yuh Lin ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Glucosamine; Inflammation; Lipopolysaccharide; Lung; Nuclear factor kappa b

Indexed keywords

CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; GAMMA INTERFERON; GLUCOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; GENE EXPRESSION; LUNG ALVEOLUS EPITHELIUM; LUNG EDEMA; LUNG LAVAGE; LUNG PARENCHYMA; NEUTROPHIL; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; GLUCOSAMINE; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LUNG; MALE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PNEUMOCYTES; PNEUMONIA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84890052619     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0022OC     Document Type: Article

References (65)

1. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003;14:523-535.
2. Lafferty EI, Qureshi ST, Schnare M. The role of Toll-like receptors in acute and chronic lung inflammation. J Inflamm (Lond) 2010;7:57-70.
3. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM, Gadek JE. Lung neutrophils in the adult respiratory distress syndrome: clinical and pathophysiologic significance. Am Rev Respir Dis 1986;133:218-225.
4. Rinaldo JE, Borovetz H. Deterioration of oxygenation and abnormal lung microvascular permeability during resolution of leukopenia in patients with diffuse lung injury. Am Rev Respir Dis 1985;131:579-583.
5. Dinarello CA. Anti-cytokine therapies in response to systemic infection. J Investig Dermatol Symp Proc 2001;6:244-250.
6. Offer S, Shoseyov D, Bibi H, Eliraz A, Madar Z. A leukotriene receptor antagonist modulates iNOS in the lung and in a leukotriene-free cell model. Nitric Oxide 2003;9:10-17.
7. Chorley BN, Li Y, Fang S, Park JA, Adler KB. (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS. Am J Respir Cell Mol Biol 2006;34:119-127.
8. Ji DB, Xu B, Liu JT, Ran FX, Cui JR. β-escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog 2011;50:945-960.
9. Turpeinen T, Nieminen R, Taimi V, Heittola T, Sareila O, Clark AR, Moilanen E, Korhonen R. Dual specificity phosphatase 1 regulates human inducible nitric oxide synthase expression by p38 MAP kinase. Mediators Inflamm 2011;2011:127587.
10. Tyagi A, Agarwal C, Dwyer-Nield LD, Singh RP, Malkinson AM, Agarwal R. Silibinin modulates TNF-α and IFN-γ mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog 2012;51:832-842.
11. Poljakovic M, Nygren JM, Persson K. Signalling pathways regulating inducible nitric oxide synthase expression in human kidney epithelial cells. Eur J Pharmacol 2003;469:21-28.
12. Kelly GS. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev 1998;3:27-39.
13. Dahmer S, Schiller RM. Glucosamine. Am Fam Physician 2008;78:471-476.
14. Talent JM, Gracy RW. Pilot study of oral polymeric N-acetyl-D-glucosamine as a potential treatment for patients with osteoarthritis. Clin Ther 1996;18:1184-1190.
15. D'Ambrosio E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981;2:504-508.
16. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev 2011;91:221-264.
17. Xing R, Liu S, Guo Z, Yu H, Li C, Ji X, Feng J, Li P. The antioxidant activity of glucosamine hydrochloride in vitro. Bioorg Med Chem 2006;14:1706-1709.
18. Fang C, Peng M, Li G, Tian J, Yin D. New functions of glucosamine as a scavenger of the lipid peroxidation product malondialdehyde. Chem Res Toxicol 2007;20:947-953.
19. Crolle G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980;7:104-109.
20. Yomogida S, Kojima Y, Tsutsumi-Ishii Y, Hua J, Sakamoto K, Nagaoka I. Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats. Int J Mol Med 2008;22:317-323.
21. Yomogida S, Hua J, Sakamoto K, Nagaoka I. Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med 2008;22:205-211.
22. Tsai CY, Lee TS, Kou YR, Wu YL. Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem 2009;108:489-498.
23. Wu YL, Kou YR, Ou HL, Chien HY, Chuang KH, Liu HH, Lee TS, Tsai CY, Lu ML. Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol 2010;635:219-226.
24. Mehta S. The effects of nitric oxide in acute lung injury. Vascul Pharmacol 2005;43:390-403.
25. Su WY, Day BJ, Kang BH, Crapo JD, Huang YC, Chang LY. Lung epithelial cell-released nitric oxide protects against PMN-mediated cell injury. Am J Physiol 1996;271:L581-L586.
26. Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980;7:110-114.
27. Braham R, Dawson B, Goodman C. The effect of glucosamine supplementation on people experiencing regular knee pain. Br J Sports Med 2003;37:45-49, discussion 49.
28. Barclay TS, Tsourounis C, McCart GM. Glucosamine. Ann Pharmacother 1998;32:574-579.
29. Setnikar I, Giachetti C, Zanolo G. Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat. Pharmatherapeutica 1984;3:538-550.
30. Kirkham SG, Samarasinghe RK. Review article: glucosamine. J Orthop Surg (Hong Kong) 2009;17:72-76.
31. Meininger CJ, Kelly KA, Li H, Haynes TE, Wu G. Glucosamine inhibits inducible nitric oxide synthesis. Biochem Biophys Res Commun 2000;279:234-239.
32. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci 2002;5:181-184.
33. Kim CH, Choi YS, Cheong KA, Lee AY. Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC/Nga mice. Int Immunopharmacol 2013;15:424-432.
34. Kim CH, Cheong KA, Park CD, Lee AY. Glucosamine improved atopic dermatitis-like skin lesions in NC/Nga mice by inhibition of Th2 cell development. Scand J Immunol 2011;73:536-545.
35. Chang YH, Horng CT, Chen YH, Chen PL, Chen CL, Liang CM, Chien MW, Chen JT. Inhibitory effects of glucosamine on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci 2008;49:5441-5449.
36. Yinnon AM, Butnaru A, Raveh D, Jerassy Z, Rudensky B. Klebsiella bacteraemia: community versus nosocomial infection. QJM 1996;89:933-941.
37. Schurr JR, Young E, Byrne P, Steele C, Shellito JE, Kolls JK. Central role of Toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria. Infect Immun 2005;73:532-545.
38. Chung MJ, Park JK, Park YI. Anti-inflammatory effects of low-molecular weight chitosan oligosaccharides in IgE-antigen complex-stimulated RBL-2H3 cells and asthma model mice. Int Immunopharmacol 2012;12:453-459.
39. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-1349.
40. Ulich TR, Watson LR, Yin SM, Guo KZ, Wang P, Thang H, Del Castillo J. The intratracheal administration of endotoxin and cytokines: I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate. Am J Pathol 1991;138:1485-1496.
41. Quinton LJ, Nelson S, Zhang P, Boé DM, Happel KI, Pan W, Bagby GJ. Selective transport of cytokine-induced neutrophil chemoattractant from the lung to the blood facilitates pulmonary neutrophil recruitment. Am J Physiol Lung Cell Mol Physiol 2004;286:L465-L472.
42. Van Zoelen MA, Verstege MI, Draing C, De Beer R, Van'tVeer C, Florquin S, Bresser P, Van Der Zee JS, Te Velde AA, Von Aulock S, et al. Endogenous MCP-1 promotes lung inflammation induced by LPS and LTA. Mol Immunol 2011;48:1468-1476.
43. Amano H, Morimoto K, Senba M, Wang H, Ishida Y, Kumatori A, Yoshimine H, Oishi K, Mukaida N, Nagatake T. Essential contribution of monocyte chemoattractant protein-1/C-C chemokine ligand-2 to resolution and repair processes in acute bacterial pneumonia. J Immunol 2004;172:398-409.
44. Henson PM, Johnston RB Jr. Tissue injury in inflammation: oxidants, proteinases, and cationic proteins. J Clin Invest 1987;79:669-674.
45. Edelson PJ, Cohn ZA. Peroxidase-mediated mammalian cell cytotoxicity. J Exp Med 1973;138:318-323.
46. Van Der Vliet A, Eiserich JP, Cross CE. Nitric oxide: a pro-inflammatory mediator in lung disease? Respir Res 2000;1:67-72.
47. Madjdpour L, Kneller S, Booy C, Pasch T, Schimmer RC, Beck-Schimmer B. Acid-induced lung injury: role of nuclear factor-kappaB. Anesthesiology 2003;99:1323-1332.
48. Beck-Schimmer B, Madjdpour C, Kneller S, Ziegler U, Pasch T, Wüthrich RP, Ward PA, Schimmer RC. Role of alveolar epithelial ICAM-1 in lipopolysaccharide-induced lung inflammation. Eur Respir J 2002;19:1142-1150.
49. Kwon S, George SC. Synergistic cytokine-induced nitric oxide production in human alveolar epithelial cells. Nitric Oxide 1999;3:348-357.
50. Xu W, Zheng S, Dweik RA, Erzurum SC. Role of epithelial nitric oxide in airway viral infection. Free Radic Biol Med 2006;41:19-28.
51. Lee H, Pespeni M, Roux J, Dennery PA, Matthay MA, Pittet JF. HO-1 induction restores c-AMP-dependent lung epithelial fluid transport following severe hemorrhage in rats. FASEB J 2005;19:287-289.
52. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004;500:255-266.
53. Haas MJ, Wong NC, Mooradian AD. Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. Metabolism 2004;53:766-771.
54. Yoshida H, Kwon AH, Kaibori M, Tsuji K, Habara K, Yamada M, Kamiyama Y, Nishizawa M, Ito S, Okumura T. Edaravone prevents iNOS expression by inhibiting its promoter transactivation and mRNA stability in cytokine-stimulated hepatocytes. Nitric Oxide 2008;18:105-112.
55. Zhou R, Gong AY, Eischeid AN, Chen XM. miR-27b targets KSRP to coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum infection. PLoS Pathog 2012;8:e1002702.
56. Scotto D'Abusco A, Politi L, Giordano C, Scandurra R. A peptidylglucosamine derivative affects IKKalpha kinase activity in human chondrocytes. Arthritis Res Ther 2010;12:R18.
57. Xing D, Gong K, Feng W, Nozell SE, Chen YF, Chatham JC, Oparil S. O-GlcNAc modification of NFκB p65 inhibits TNF-α-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS ONE 2011;6:e24021.
58. Allison DF, Wamsley JJ, Kumar M, Li D, Gray LG, Hart GW, Jones DR, Mayo MW. Modification of RelA by O-linked N-acetylglucosamine links glucose metabolism to NF-κB acetylation and transcription. Proc Natl Acad Sci USA 2012;109:16888-16893.
59. Li MD, Ruan HB, Singh JP, Zhao L, Zhao T, Azarhoush S, Wu J, Evans RM, Yang X. O-GlcNAc transferase is involved in glucocorticoid receptor-mediated transrepression. J Biol Chem 2012;287:12904-12912.
60. Horsch M, Hoesch L, Vasella A, Rast DM. N-acetylglucosaminono-1, 5-lactone oxime and the corresponding (phenylcarbamoyl) oxime: novel and potent inhibitors of beta-N-acetylglucosaminidase. Eur J Biochem 1991;197:815-818.
61. Du Q, Zhang X, Cardinal J, Cao Z, Guo Z, Shao L, Geller DA. Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res 2009;69:3764-3771.
62. Ravichandran K, Tyagi A, Deep G, Agarwal C, Agarwal R. Interleukin-1beta-induced iNOS expression in human lung carcinoma A549 cells: involvement of STAT and MAPK pathways. Indian J Exp Biol 2011;49:840-847.
63. Chan ED, Riches DW. IFN-gamma 1 LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38 (MAPK) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001;280:C441-C450.
64. Zhang B, Perpetua M, Fulmer M, Harbrecht BG. JNK signaling involved in the effects of cyclic AMP on IL-1beta plus IFNgamma-induced inducible nitric oxide synthase expression in hepatocytes. Cell Signal 2004;16:837-846.
65. Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 2002;367:97-105.